MON-744 - Assessing the Participant Experience with Fibrodysplasia Ossificans Progressiva: Qualitative Interviews from the OPTIMA Trial

Abstract Poster Presenter(s)

• JG

  Jing Gu, Ph.D.

  REGENERON PHARM INC
  Sleepy Hollow, NY, United States

Co-Author(s)

• CH

  Christopher Hartford, MPH

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• SM

  Susan Martin, MSPH

  RTI Health Solutions
  Durham, United States
• NH

  Nimanee Harris, MPH

  RTI Health Solutions
  Durham, United States
• RP

  Riccardo Papa, MD

  IRCCS Istituto Giannina Gaslini
  Genova, Italy
• PD

  Patricia Delai, MD

  Hospital Israelita Albert Einstein, Instituto de Ensino e Pesquisa
  São Paulo, Brazil
• 

  Richard Keen, MD PhD

  Royal National Orthopaedic Hospital
  Stanmore, United Kingdom
• KM

  Kenichi Mishima, MD

  Nagoya University Hospital
  Nagoya, Japan
• KD

  Kathryn M. Dahir, MD

  Vanderbilt University Medical Center, United States
• NU

  Naoto Uemura, MD, PhD

  Oita University
  Oita, Japan
• TF

  Toshifumi Fujiwara, MD

  Kyushu University Hospital
  Fukuoka, Japan

Senior Author/Primary Investigator(s)

• SR

  Susan Rhee, MD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, New York, United States
• RP

  Robert Pordy, MD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, New York, United States
• RS

  Robert J. Sanchez, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States